Health Care·Biotechnology·$2.7B
IDEAYA Biosciences is a biotechnology company focused on developing targeted therapies for cancer. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as advancements in personalized medicine continue to evolve.
EPS
Earnings per share is a key indicator of profitability, and investors will be keen to see if the company can improve its financial performance.
Revenue
While specific revenue estimates are not available, any indication of revenue growth or new partnerships will be critical for assessing the company's market position.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
2Q
EPS Beat Rate
38%
Avg EPS Surprise
+8282.07%
Avg Stock Reaction
-2.75%
In the last quarter, IDEAYA reported an EPS of -$0.94, which was better than the expected -$1.03, resulting in a slight stock increase. However, revenue details were not disclosed, leaving some uncertainty about overall financial health.
Management Promises & Guidance
Investors are cautiously optimistic about IDEAYA's upcoming earnings report, especially given the recent EPS surprise. However, the lack of revenue guidance and management commentary adds a layer of uncertainty.
Bull Case
If IDEAYA can show significant progress in clinical trials and improved EPS, it could lead to a strong positive reaction from investors.
Bear Case
Conversely, if the company fails to meet expectations or provides disappointing updates on clinical trials, it could lead to a sharp decline in stock price.
EPS
N/AEarnings per share is a key indicator of profitability, and investors will be keen to see if the company can improve its financial performance.
Revenue
N/AWhile specific revenue estimates are not available, any indication of revenue growth or new partnerships will be critical for assessing the company's market position.
Clinical Trial Updates
N/AUpdates on ongoing clinical trials can significantly impact investor sentiment and stock performance, as they reflect the company's progress in drug development.
The print will turn on these two things.
Q1
What updates will be provided on the ongoing clinical trials?
The success or failure of these trials can significantly influence the company's future and investor confidence.
Q2
Can the company improve its EPS beyond the previous quarter's surprise?
A better-than-expected EPS could signal a turnaround in profitability, attracting more investor interest.
Why consensus could be wrong
The Street may underestimate the potential impact of positive clinical trial results, which could significantly boost investor sentiment and stock price.
Supporting Evidence
The options market is pricing a 13.1% move, indicating expectations of volatility that may not align with historical performance.
The average EPS surprise in the last quarter was positive, suggesting potential for continued improvement.
Key Risk
If clinical trial updates are significantly positive, it could shift the narrative and drive the stock higher.
Pre-commit to what would confirm each case.
The market is weighing the potential for growth against the risks of ongoing clinical trials and financial performance.
Bull Confirmed If
Demonstrating progress in clinical trials and achieving an EPS of better than -$0.80 would confirm the bull case.
Bear Confirmed If
Failing to provide positive updates on clinical trials or reporting an EPS worse than -$1.00 would confirm the bear case.
Implied Move
±13.1%
Historical Avg
±4.4%
The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±13.1% while IDYA has averaged ±4.4% over the last 8 prints — setup is pricing rich.
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
n=30Fade rate: 7 of 20 (35%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 20 (65%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.1%, with a raw directional average of +1.9% (modestly positive historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If IDEAYA beats expectations, history suggests a potential stock increase of around 1.24%, confirming a positive outlook.
In-Line / Cautious
If results are in line with expectations but lack strong guidance, the stock may see minimal movement as investors remain cautious.
Miss
If the company misses expectations, history suggests a decline of around 5.14%, reflecting investor disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENBRIDGE INC
May 8, 2026